Hims & Hers Health has contributed $1 million to President-elect Donald Trump’s inauguration fund, a move aimed at gaining favor with the new administration, as confirmed by CNBC. The company, known for its direct-to-consumer health treatments for conditions like weight loss and erectile dysfunction, joins other tech firms in making similar donations, including OpenAI and Meta. Hims & Hers stated its commitment to supporting leaders who aim to improve the U.S. healthcare system. The company gained prominence last year for its weight loss program, which includes prescribing compounded semaglutide, a cheaper alternative to Novo Nordisk’s medications Ozempic and Wegovy. Despite its success, the future of compounded GLP-1s is uncertain, especially with mixed opinions from Trump’s circle. Robert F. Kennedy Jr., Trump’s HHS pick, advocates for lifestyle changes over drugs, while Dr. Marty Makary, set to lead the FDA, has ties to a firm involved in telehealth for GLP-1 prescriptions. In contrast, Elon Musk supports lowering the cost of GLP inhibitors. Hims & Hers has pledged to collaborate with the incoming administration to advocate for the value of these medications.
